137 related articles for article (PubMed ID: 2675183)
1. Bone and soft-tissue lesions: diagnosis with combined H-1 MR imaging and P-31 MR spectroscopy.
Negendank WG; Crowley MG; Ryan JR; Keller NA; Evelhoch JL
Radiology; 1989 Oct; 173(1):181-8. PubMed ID: 2675183
[TBL] [Abstract][Full Text] [Related]
2. [Changes of 3-tesla 31P-MR spectroscopy of bone and soft tissue tumors].
Qi ZH; Li CF; Ma XX; Li ZF; Zhang K; Yu DX
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):442-6. PubMed ID: 19950555
[TBL] [Abstract][Full Text] [Related]
3. [31P-MR spectroscopy of bone and soft tissue lesions].
Kitagawa A; Saeki M; Imamura K; Ohashi K; Ishikawa T; Nakajima H; Takagi M
Nihon Igaku Hoshasen Gakkai Zasshi; 1995 Dec; 55(15):1017-24. PubMed ID: 8587841
[TBL] [Abstract][Full Text] [Related]
4. Characterization of bone and soft-tissue tumors with in vivo 1H MR spectroscopy: initial results.
Wang CK; Li CW; Hsieh TJ; Chien SH; Liu GC; Tsai KB
Radiology; 2004 Aug; 232(2):599-605. PubMed ID: 15286325
[TBL] [Abstract][Full Text] [Related]
5. Preliminary study of 3T 1H MR spectroscopy in bone and soft tissue tumors.
Qi ZH; Li CF; Li ZF; Zhang K; Wang Q; Yu DX
Chin Med J (Engl); 2009 Jan; 122(1):39-43. PubMed ID: 19187615
[TBL] [Abstract][Full Text] [Related]
6. MR imaging of soft-tissue masses: diagnostic efficacy and value of distinguishing between benign and malignant lesions.
Moulton JS; Blebea JS; Dunco DM; Braley SE; Bisset GS; Emery KH
AJR Am J Roentgenol; 1995 May; 164(5):1191-9. PubMed ID: 7717231
[TBL] [Abstract][Full Text] [Related]
7. Combined MR imaging and spectroscopy of bone and soft tissue tumors.
Zlatkin MB; Lenkinski RE; Shinkwin M; Schmidt RG; Daly JM; Holland GA; Frank T; Kressel HY
J Comput Assist Tomogr; 1990; 14(1):1-10. PubMed ID: 2153717
[TBL] [Abstract][Full Text] [Related]
8. Benign and malignant musculoskeletal lesions: dynamic contrast-enhanced MR imaging--parametric "first-pass" images depict tissue vascularization and perfusion.
Verstraete KL; De Deene Y; Roels H; Dierick A; Uyttendaele D; Kunnen M
Radiology; 1994 Sep; 192(3):835-43. PubMed ID: 8058957
[TBL] [Abstract][Full Text] [Related]
9. Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study.
Bartella L; Morris EA; Dershaw DD; Liberman L; Thakur SB; Moskowitz C; Guido J; Huang W
Radiology; 2006 Jun; 239(3):686-92. PubMed ID: 16603660
[TBL] [Abstract][Full Text] [Related]
10. Osseous invasion by soft-tissue sarcoma: assessment with MR imaging.
Elias DA; White LM; Simpson DJ; Kandel RA; Tomlinson G; Bell RS; Wunder JS
Radiology; 2003 Oct; 229(1):145-52. PubMed ID: 14519874
[TBL] [Abstract][Full Text] [Related]
11. Benign and malignant masses. MR imaging differentiation.
Weatherall PT
Magn Reson Imaging Clin N Am; 1995 Nov; 3(4):669-94. PubMed ID: 8564689
[TBL] [Abstract][Full Text] [Related]
12. Soft-tissue tumors: value of static and dynamic gadopentetate dimeglumine-enhanced MR imaging in prediction of malignancy.
van Rijswijk CS; Geirnaerdt MJ; Hogendoorn PC; Taminiau AH; van Coevorden F; Zwinderman AH; Pope TL; Bloem JL
Radiology; 2004 Nov; 233(2):493-502. PubMed ID: 15459325
[TBL] [Abstract][Full Text] [Related]
13. Characterization of musculoskeletal lesions on 3-T proton MR spectroscopy.
Fayad LM; Barker PB; Jacobs MA; Eng J; Weber KL; Kulesza P; Bluemke DA
AJR Am J Roentgenol; 2007 Jun; 188(6):1513-20. PubMed ID: 17515370
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of early imaging response after chemoembolization of hepatocellular carcinoma by phosphorus-31 magnetic resonance spectroscopy-initial experience.
Yuan Z; Ye XD; Dong S; Xu LC; Xiao XS
J Vasc Interv Radiol; 2011 Aug; 22(8):1166-73. PubMed ID: 21703872
[TBL] [Abstract][Full Text] [Related]
15. 31-P mr spectroscopy of a leg lymphangiosarcoma.
Kiricuta IC; Bluemm RG; Krawzak HW; Rühl J; Beyer HK
Lymphology; 1994 Jun; 27(2):82-9. PubMed ID: 8078364
[TBL] [Abstract][Full Text] [Related]
16. Preliminary study of proton magnetic resonance spectroscopy in bone and soft tissue tumors: an unassigned signal at 2.0-2.1 ppm may be a possible indicator of malignant neuroectodermal tumor.
Oya N; Aoki J; Shinozaki T; Watanabe H; Takagishi K; Endo K
Radiat Med; 2000; 18(3):193-8. PubMed ID: 10972550
[TBL] [Abstract][Full Text] [Related]
17. Soft-tissue sarcomas: MR imaging and MR spectroscopy for prognosis and therapy monitoring. Work in progress.
Dewhirst MW; Sostman HD; Leopold KA; Charles HC; Moore D; Burn RA; Tucker JA; Harrelson JM; Oleson JR
Radiology; 1990 Mar; 174(3 Pt 1):847-53. PubMed ID: 2154837
[TBL] [Abstract][Full Text] [Related]
18. Magnetic resonance angiography without contrast enhancement medium in bone and soft tissue tumors.
Doi H; Ono A; Kawai A; Morimoto Y; Kunisada T; Nakata E; Ozaki T
Oncol Rep; 2006 Mar; 15(3):681-5. PubMed ID: 16465430
[TBL] [Abstract][Full Text] [Related]
19. Primary musculoskeletal tumors: examination with MR imaging compared with conventional modalities.
Pettersson H; Gillespy T; Hamlin DJ; Enneking WF; Springfield DS; Andrew ER; Spanier S; Slone R
Radiology; 1987 Jul; 164(1):237-41. PubMed ID: 3588912
[TBL] [Abstract][Full Text] [Related]
20. The role of MRS in the differentiation of benign and malignant soft tissue and bone tumors.
Doganay S; Altinok T; Alkan A; Kahraman B; Karakas HM
Eur J Radiol; 2011 Aug; 79(2):e33-7. PubMed ID: 21376496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
